Maxim Group Upgrades Theriva Biologics to Buy, Announces $1 Price Target

Maxim Group analyst Jason McCarthy has upgraded Theriva Biologics (AMEX:TOVX) from a 'Hold' rating to 'Buy' and set a price target of $1 for the stock. This upgrade indicates a positive outlook for the company's performance in the market.